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Abstract — A suitable management of the pharmaceutical 
property is needed and helpful to design a desired 
nanoparticulate delivery system, which includes the carrier 
nature, particle size and size distribution, morphology, 
surfactant stabiliser according to the technique applied, drug-
loading ratio and encapsulation efficiency, surface property, 
etc. All will influence the in vitro release, in vivo behaviour 
and tissue distribution of administered particulate drug 
loaded nanoparticles. The main purpose of the present work 
was to determine the effect of drug loading ratio when 
employing TPGS as surfactant stabiliser and/or matrix 
material to improve the nanoparticulate formulation. The 
model drug employed was paclitaxel.  
 
Index Terms—Biomaterials; Drug delivery; Surfactant 
stabiliser; Paclitaxel; D-α-tocopheryl polyethylene glycol 1000 
succinate. 
 
 
I. INTRODUCTION 
he major goal in designing polymeric nanoparticles for 
delivery of a specific drug includes realising the 
controlled and targeted release of the active agent to the 
specific site of action at the therapeutically optimal rate. 
One of the most important concerns is a clear 
understanding of the pharmaceutical property of the 
prepared nanoparticles, including carrier nature, particle 
size and size distribution, surface and bulk morphology, 
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surface chemistry, surface charge, thermogram property, 
drug encapsulation efficiency (EE) and drug release 
kinetics of the particles, etc. All may have significant 
influence on the in vivo behaviour and tissue distribution of 
the drug loaded in the nanoparticles. With regard to the 
manufacture of polymeric nanoparticles, the solvent 
extraction/evaporation method is one of the most widely 
employed techniques and poly (vinyl alcohol) (PVA) is the 
most commonly used emulsifier in the process. However, 
as a functional surfactant, PVA tends an interconnected 
network with the polymer at the surface and is difficult to 
be removed after emulsification despite repeated washing 
[1]. It has been found that nanoparticles with higher 
amount of residual PVA have relatively lower cellular 
uptake [2]. PVA emulsified nanoparticles are thus not 
satisfactorily biocompatible and may be toxic for human 
body. Recently, we have successfully used d-α-tocopheryl 
polyethylene glycol 1000 succinate (vitamin E TPGS or 
TPGS) in the formulation of poly(DL-lactide-co-glycolide) 
(PLGA) nanoparticles, which can be treated either as the 
surfactant stabiliser added in the water phase or as a matrix 
component material added in the oil phase in the process 
[3, 4]. The model drug adopted was paclitaxel, which is 
one of the best antineoplastic drugs found from the nature 
in the past decades. Paclitaxel has excellent therapeutic 
efficacy against a wide spectrum of cancers, especially for 
ovarian and breast cancer. The clinical application of this 
drug has been limited due to its poor aqueous solubility. In 
its current clinical administration, an adjuvant called 
Cremophor EL is needed, which has been found 
responsible for most of the serious side effects of the 
dosage form and these include hypersensitivity reaction, 
nephrotoxicity, neurotoxicity and cardiotoxicity [5,6]. The 
polymeric nanoparticles have promising potential to solve 
the problems caused by Cremophor EL and could provide 
an alternative dosage form for clinical administration of 
paclitaxel.  
 
There are various parameters in the manufacturing 
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process which determine the physicochemical and 
pharmaceutical properties of the paclitaxel loaded 
polymeric nanoparticles such as the polymer type, its 
molecular weight/co-polymer ratio, the emulsifier 
employed, the drug loading ratio, the oil to water phase 
ratio, the mechanical strength of mixing, the pH and the 
temperature, etc. The present work was focused on the 
influence of the emulsifier type/quantity and the drug 
loading ratio on the physicochemical and pharmaceutical 
properties of the paclitaxel loaded PLGA/TPGS 
nanoparticles, which were manufactured by a modified 
single emulsion solvent extraction/evaporation technique. 
TPGS was introduced first as an emulsifier added in the 
water phase and then as a matrix material component 
added in the oil phase at various mole ratios in the 
emulsification process. Paclitaxel was loaded at various 
levels. Various equipments were used to characterise and 
analyse the produced nanoparticles such as the laser light 
scattering (LLS) for size and size distribution, the atomic 
force microscopy (AFM) and scanning electron 
microscopy (SEM) for surface morphology, the X-ray 
photoelectron spectroscopy (XPS) for surface chemistry, 
the different scanning calorimetry (DSC) for thermal 
properties, and the high performance liquid 
chromatography (HPLC) for drug encapsulation efficiency 
and the measurement of in vitro release kinetics. We found 
that the drug encapsulation efficiency and the in vitro 
release behaviour could be significantly influenced by the 
drug loading ratio and the type and quantity of the 
surfactant stabiliser used and that vitamin E TPGS could be 
a novel and effective emulsifier as well as a nanoparticle 
matrix component material. Compared with PVA, the 
TPGS emulsified nanoparticles can have more favourable 
properties such as higher encapsulation efficiency (up to 
100%) and could be easier to be removed from particles 
surface after the nanoemulsification.  
 
 
II. MATERIALS AND METHODS 
A. Material 
Poly (DL-lactide-co-glycolide) (PLGA, L/G=50/50, 
MW (40,000-75,000) and polyvinyl alcohol (PVA, MW 
30,000-70,000, the degree of hydrolysis is 87 to 90 %) 
were purchased from Sigma Chemical Co., USA. 
Paclitaxel was purchased from Dabur India Limited, India. 
TPGS (d-alpha tocopheryl polyethylene glycol 1000 
succinate) was purchased from Eastman Chemical 
Company, USA. Acetonitrile (HPLC grade) was used as 
the mobile phase in HPLC and was purchased from 
Mallinckrodt Baker Inc. USA. Ultra-high pure water 
produced by UHQ Water Purification System was utilised 
for HPLC analysis. Deionised water was used throughout 
the experiment. The measurement of in vitro release was 
carried out in phosphate buffered saline (PBS), which was 
purchased from Sigma Diagnostics. All other chemicals 
used were of reagent grade and were used as received 
without further purification. 
 
B. Methods  
Fabrication and Collection of Nanoparticles --- The 
nanoparticles were fabricated by a modified oil-in-water 
(o/w) single-emulsion solvent evaporation/extraction 
technique. Typically, known amounts of the polymer, 
TPGS and paclitaxel at a certain ratio were dissolved in 
dichloromethane (DCM), which was stirred using a 
magnetic stirrer until all materials were dissolved. The 
organic phase was poured into the stirred aqueous 
solution containing one of the two surfactant stabilisers 
and sonicated simultaneously with energy output of 12W 
in a pulse mode using a sonicator (Misonix Incorporated, 
USA). The formed o/w emulsion was stirred by magnetic 
stirrer continuously for at least six hours to evaporate the 
organic solvent off. During the process, the micro/nano- 
droplets were solidified in the aqueous system. The 
resultant sample was separated and collected by 
centrifugation (11000 rpm, 10 min, 16ºC. 5810R, 
Eppendorf AG, Germany). The supernatant was decanted 
and pure deionised water was poured into the centrifuge 
tube that was well shaken to wash the collected 
nanoparticles 3-4 times to remove the surfactant residue. 
The produced suspension was dried under lyophilisation 
(Alpha-2 Martin Christ Freeze Dryers, Germany) to 
obtain the fine powder of nanoparticles, which was 
placed and kept in vacuum dessicator.  
 
Characterization of Nanoparticles --- The atomic force 
microscopy (AFM, MultimodeTM Scanning Probe 
Microscope, Digital Instruments, USA) and the scanning 
electron microscopy (SEM, JSM-5600 LV, JEOL USA, 
Inc.) were conducted to observe the shape and surface 
morphology of the nanoparticles. AFM was performed by 
the tapping mode. SEM required a coating of the sample 
with platinum, which was done in an Auto Fine Coater 
(JFC-1300, JEOL USA). The particle size and size 
distribution of the nanoparticles were measured by the 
laser light scattering (LLS, 90 Plus Particle Sizer, 
Brookhaven Instruments Co. USA). Suitable amount of the 
dried nanoparticles from each formulation was suspended 
in deionised water and was sonicated for a suitable time 
period before the measurement. The volume mean 
diameter, size distribution and polydispersity of the 
resulting homogeneous suspension was determined. The 
surface chemistry of the nanoparticles was analysed by X-
ray Photoelectron Spectroscopy (XPS, SXIS His-165 Ultra, 
Kratos Axis HSi, Kratos Analytical, Shimadzu 
Corporation, Japan). Peak curve fitting of the C1s (atomic 
orbital 1s of carbon) envelope was performed using 
XPSPeak 4.1 software. The thermal characteristics of drug 
loaded nanoparticles were analysed by the differential 
scanning calorimetry (DSC 822e, Mettler Toledo, STARe 
 
 
software), and the glass transition temperatures (Tg) or 
melting point (Tm) was measured. As a control, the pure 
material of paclitaxel, PLGA, TPGS, PVA and the physical 
mixture of paclitaxel with placebo nanoparticles 
(paclitaxel: placebo nanoparticles = 1:9) was also analysed.  
 
 Incorporation Capability and In Vitro Release of 
Paclitaxel Loaded nanoparticles --- The amount of 
entrapped paclitaxel in nanoparticles was detected in 
triplicate by HPLC (Agilent LC1100). A reverse phase 
Inertsil® ODS-3 column (150 x 4.6 mm ID, pore size 5 
µm, GL Science, Tokyo, Japan) was used. The mobile 
phase consisted of a mixture of acetonitrile and water 
(50/50 v/v) and was delivered at a flow rate of 1 ml/min 
with a pump (HP 1100 High Pressure Gradient Pump). The 
column effluent was detected at 227 nm with a variable 
wavelength detector (HP 1100 VWD). The encapsulation 
efficiency of paclitaxel in nanoparticles was determined as 
the mass ratio of the entrapped paclitaxel in nanoparticles 
to the theoretical amount of paclitaxel used in the 
preparation. Meanwhile, the recovery efficiency factor on 
encapsulation efficiency was determined as the ratio of the 
paclitaxel concentration obtained from HPLC to the 
theoretical concentration of the prepared solution which 
was obtained by dissolving the physical mixture of pure 
paclitaxel and placebo nanoparticles with relevant ratio in 
acetonitrile. The resultant factor was 100%, which means 
that 100% of originally loaded amount of paclitaxel could 
be detected. No correction was needed. The in vitro release 
of paclitaxel from nanoparticles was measured in triplicate 
in PBS at pH 7.4. Ten mg of paclitaxel-loaded 
nanoparticles were suspended in 10 ml of PBS in a screw-
capped tube and the tube was placed in an orbital shaker 
water bath (GFL-1086, Lee Hung Technical Company, 
Bukit Batok Industrial Park A, Singapore). The water bath 
was maintained at 37oC and shaken horizontally at 120 
min-1. At particular time intervals, the tubes were taken out 
from the water bath and were centrifuged at 12000 rpm for 
12 minutes. The supernatant solution was collected from 
each tube for HPLC analysis and the precipitated 
nanoparticles were resuspended in 10 ml of fresh PBS and 
then put back into the water bath to continuous release 
measurement. The collected supernatant solution was 
extracted with 1 ml of DCM. A mixture of acetonitrile and 
water (50:50 v/v) was added to the extracted paclitaxel 
after the DCM had evaporated. The resultant solution was 
put into HPLC vial for HPLC analysis by the same 
procedure previously described. Similarly, the extraction 
recovery efficiency was measured due to inefficient 
extraction. A known mass of pure paclitaxel was treated 
with the same extraction procedure described above. The 
determined factor was 37%. That means the extracted 
solution contained 37% of the original paclitaxel after all 
the related processes. The data obtained from the detection 
were corrected accordingly. 
 
III. RESULTS AND DISCUSSION 
 
Morphology, Size and Size Distribution of Prepared 
Nanoparticles --- AFM and SEM were utilised to study the 
morphological property of the nanoparticles. From the 
SEM images (Fig.1), all nanoparticles from all 
formulations  
 
 
 
Fig.1. SEM images of nanoparticles composed of 
PLGA/TPGS with TPGS as emulsifier (the bar was 1 µm). 
 
 
 
 
 
Fig.2. AFM images of nanoparticles composed of 
PLGA/TPGS with TPGS as emulsifier. 
 
 
displayed in spherical shapes and did not show aggregation 
although the particles might be too small for the resolving 
power of SEM. There was no obviously difference 
 
 
amongst different formulations of nanoparticles. Under 
AFM with higher resolution (Fig.2), the distinct spherical 
nanoparticles could be observed, both single nanoparticle 
and multi-nanoparticles. The particles were closed and 
sorted out well from each other without adhesion or 
cohesion. The surface was relatively smooth. The result 
showed that the difference in drug loading-ratio had no 
significant influence on the nanoparticles morphology, no 
matter the particles were composed of polymer only or the  
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Fig.3. Size distribution of nanoparticles composed of 
PLGA and TPGS with TPGS as emulsifier and with 
various drug-loading ratios.    
 
 
mixture of polymer and TPGS, and emulsified by PVA or 
TPGS. Fig. 3 illustrated the representative size distribution 
of the nanoparticles prepared with various drug-loading 
ratio. Summarily, the noparticles reached the smallest when 
both TPGS and PVA were employed into the formulation. 
And PVA emulsified nanoparticles were relatively smaller 
than the TPGS emulsified nanoparticles. 
 
Thermal Characteristic --- The pure paclitaxel showed 
an endothermic peak of melting at about 223.0 ºC but no 
related peak displayed for all the prepared nanoparticles 
with or without drug entrapped. However, the physical 
mixture of pure paclitaxel and placebo nanoparticles gave a 
broadened peak shifted to a lower temperature at about 220 
ºC. The content of paclitaxel in the physical mixture (the 
ratio of paclitaxel to placebo nanoparticles was 1:9) was 
even higher than that in the nanoparticles (12% drug 
loading ratio). The result concluded that the paclitaxel 
entrapped in the nanoparticles was in an amorphous or 
disordered-crystalline phase of a molecular dispersion or a 
solid solution state in the matrix of polymer or polymer 
mixed with TPGS after the fabrication and all related 
treatment, no matter the drug loading was low (2%) or high 
(12%) [7]. Meanwhile, the glass transition temperature of 
the polymer PLGA employed in the nanoparticles 
formulation was not influenced significantly by the 
procedure. But the melting peak of TPGS did not 
displayed, which meant that it was made amorphous when 
blended with polymer for fabrication of nanoparticles.     
 
Surface Chemistry --- The XPS results were summarised 
in Table 1. For all samples, the elemental ratios for C and 
O were similar and did not seem to be affected by the 
difference in drug loading ratio or emulsifier. Some of the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
samples had non-zero percentages for element N although 
the percentage was low, which may indicate the presence 
of N near or at the surface of the nanoparticles. This may 
also suggest that the nanoparticles produced were in the 
form of matrix system where the drug is distributed evenly 
or random. Therefore, it is possible to observe the presence 
of the drug near or at the surface even at a very low 
amount, most of which could not be detected by the XPS. 
Nevertheless, it was expected that the drug was more 
concentrated inside the nanoparticles because the drug 
paclitaxel is highly hydrophobic, it tends to stay away from 
aqueous environment. This could be confirmed by the 
elemental distribution of nanoparticles with high drug 
loading ratio as the distribution of N near or at the surface 
did not increased along with the increased drug loading 
ratio. The even and random distribution of paclitaxel was 
also agreed with the result of DSC analysis. Besides, the 
presence of paclitaxel near or at the surface may influence 
the in vitro release behaviour that may show a high burst 
release. As to the XPS curve fitting analysis, PLGA gave 
the expected three peaks corresponding to O=C-O, C-O-
C=O and C-C/C-H, whilst PVA and TPGS gave O=C-O, 
C-OH(R) and C-C/C-H respectively. After fabrication 
procedure, all nanoparticles gave four peaks that 
 
 
corresponded to all the initial specific C1s environments. 
In comparison with the value from the basic material 
PLGA, the data from all nanoparticles displayed a 
significant increase in the region of C-OH(R) and decrease 
in the region of C-O-C=O. This suggested the distribution 
or adsorption of the emulsifier PVA or TPGS on the 
surface during the nanoparticles formation to achieve 
stabilisation of the polymer/water interface. The retaining 
of C1s envelope corresponding to C-O-C=O indicated the 
existence of PLGA at the particles surface. The analysis 
revealed that the surface of the fabricated nanoparticles 
was composed of both the matrix material PLGA and the 
surfactant stabiliser PVA or TPGS. The distribution 
percentage of each substance was approximately close to 
50 % by comparing the envelope ratio of C-OH(R) and C-
O-C=O. Another point to be highlighted is that, regarding 
the C-OH(R) coming from the emulsifier, the percentage of 
this carbon environment distributed on the nanoparticles 
surface to it at the pure material from PVA was higher than 
from TPGS, no matter if TPGS was used together with 
PLGA as matrix material. The result may suggest that the 
emulsifier molecules of PVA left on the particles surface 
was more than those of TPGS, meaning that the PVA was 
difficult to be removed away than TPGS after same 
cleaning procedure. 
 
Paclitaxel Encapsulation Efficiency --- The 
encapsulation efficiencies of the drug in all the 
nanoparticulate formulations were measured. Overall, the 
nanoparticles prepared with TPGS as emulsifier 
demonstrated higher drug encapsulation efficiencies 
compared to the ones prepared with PVA as emulsifier. 
TPGS could effectively increase the encapsulation 
efficiency up to 100% (i.e. 97.5% in sample tt2, when 
TPGS as material matrix and as surfactant stabiliser), while 
PVA could only efficiently encapsulate until 60.5 when 
PLGA was used as material in sample p3 (PLGA as 
material matrix and PVA as surfactant stabiliser) and 
65.5% in sample tp3 (when TPGS was mixed together with 
PLGA as matrix material while PVA as surfactant 
stabiliser). It could be concluded that TPGS was a more 
effective emulsifier than PVA since concentration of TPGS 
used was much lower than concentration of PVA (0.025% 
versus 1.0%). Meanwhile, there was a trend in the relation 
between the drug loading-ratio and the encapsulation 
efficiency. Generally, increase in drug loading-ratio from 
2% to 12 % resulted in an increase in the encapsulation 
efficiency although an optimal drug loading ratio might be 
confirmed by determining more points of drug loading-
ratios versus encapsulation efficiencies to probably obtain 
the correlation between them.    
 
 
 
   In Vitro Release of Paclitaxel from Various 
Nanoparticles --- Nanoparticles of various formulations 
were determined for their cumulative release of 
encapsulated paclitaxel under in vitro condition. The 
curves were showed in Fig. 4. Generally, the release 
profiles were biphasic with an initial burst attributed to the 
drug associated near particles surface, followed by a linear 
release phase.  Clearly, both the emulsifier and the drug 
loading ratio could influence the in vitro release behaviour 
significantly. A general trend was that the release rate 
decreased with the increased drug loading ratio for all 
formulations (Fig. 4, a-d). As discussed previously, the 
drug loading ratio did not have significant effects on the 
nanoparticles size and morphology. Thus, the difference in 
the release behaviour could not be related to the particle 
size. For nanoparticles of a same size, increase in the drug 
loading ratio causes their internal structure more compact, 
hindering the water penetration into the particles and hence 
less drug diffusion for the release. PVA emulsified 
nanoparticles (Sample p and Sample tp) exhibited faster 
release than those emulsified by TPGS (Sample t and 
Sample tt). This may be because TPGS is more 
hydrophobic molecule, smaller but with bigger bulk area 
and could cause more compact matrix structure, resulting 
in a lower degradation rate of the polymer and/or slower 
diffusion of the encapsulated drug.    
  
 
IV. CONCLUSION 
The present work fabricated and characterised paclitaxel 
loaded PLGA and PLGA-TPGS nanoparticle formulations 
that utilised various paclitaxel loading ratio and emulsifier. 
The results demonstrated that the pharmaceutical property 
of nanoparticles could be influenced either by paclitaxel 
loading ratio or by surfactant stabiliser. In vitro release 
characteristics were closely related to the paclitaxel loading 
ratio which was also an important formulation parameter 
on the drug encapsulation efficiency. Generally, the release 
rate decreased with the increased drug loading-ratio for all 
formulations. TPGS-emulsified nanoparticles exhibited 
slower release compared to PVA-emulsified nanoparticles. 
Initial burst release was observed for all nanoparticles 
formulation. When incorporating TPGS as material matrix 
together with PLGA, the initial burst release reduced 
compared other formulations with PLGA only as material 
matrix at same drug-loading ratio. Also in that case, the 
release rate of PVA emulsified nanoparticles was distinctly 
faster than that of TPGS emulsified nanoparticles. The 
increment was even more when paclitaxel loading ratio 
increased. The surface chemistry of the nanoparticles in 
different formulation was similar, which suggested that 
drug-loading ratio had slightly influence on the particles 
surface property. Also, PVA was difficult to be removed 
away than TPGS after same cleaning procedure. To sum 
up, both paclitaxel loading ratio and the surfactant 
stabiliser were important formulation parameters that could 
 
 
be applied to modify or alter the different pharmaceutical 
properties of nanoparticles for the controlled release of 
anticancer drug paclitaxel. As emulsifier, TPGS was 
comparable to PVA but possessed potential advantages to 
be applied.  
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Fig. 4. Release curves of paclitaxel from different 
nanoparticle formulations under in vitro condition (a: 
PLGA nanoparticles with PVA as emulsifier and different 
drug loading ratio; b: PLGA nanoparticles with TPGS as 
emulsifier and different drug loading ratio; c: PLGA-TPGS 
nanoparticles with PVA as emulsifier and different drug 
loading ratio; d: PLGA-TPGS nanoparticles with TPGS as 
emulsifier and different drug loading ratio).    
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